Skip to main content
. 2024 Jan 30;14(3):295. doi: 10.3390/diagnostics14030295

Table 2.

Clinical and instrumental characteristics at t0 in patients with negative and positive t2 HRCT.

Features Patients with Negative t2 HRCT
n (%)		 Patients with Positive t2 HRCT
n (%)		 p-Value
Gender
  • ▪

    Female;

 365 (91.0%) 36 (9.0%) 0.2101
  • ▪

    Male.

 63 (86.3%) 10 (13.7%)
Disease duration (from Raynaud onset) in months (median; Q1–Q3) (n) 77.8 (28.4–161.7) (206) 71.2 (17.4–194.1) (18) 0.7537
Skin involvement
  • ▪

    dcSSc;

 106 (86.9%) 16 (13.1%)
  • ▪

    lcSSc;

 250 (91.2%) 24 (8.8%)
  • ▪

    Only sclerodactyly;

 52 (92.9%) 4 (7.1%) 0.2832
  • ▪

    No skin involvement.

 18 0
mRSS (mean ± SD) (median; Q1-Q3) (n) 6 (3–10) (393) 7 (3–13) 0.1563
SSc-specific Antibody positivity
  • ▪

    ACA-positive;

 211 (95.9%) 9 (4.1%) 0.0001
  • ▪

    ACA-negative;

 203 (85.3%) 35 (14.7%)
  • ▪

    Topo-I-positive;

 97 (82.9%) 20 (17.1%) 0.0031
  • ▪

    Topo-I-negative;

 317 (92.4%) 26 (7.6%)
  • ▪

    RNA-Pol III-positive;

 9 (75.0%) 3 (25.0%) 0.1003
  • ▪

    RNA-Pol III-negative.

 222 (91.0%) 22 (9%)
PFTs (values reported as %predicted ±SD)
  • ▪

    t0 DLCO;

 79.0 (±16.6) 69.9 (±17.4) 0.0006
  • ▪

    t0 FVC;

 102.2 (±17.3) 94.6 (±16.2) 0.0052
  • ▪

    t1 DLCO;

 78.4 (±16.8) 68.9 (±18.6) 0.0005
  • ▪

    t1 FVC;

 101.9 (±17.9) 94.7 (±16.5) 0.0092
  • ▪

    t2 DLCO;

 78.0 (±17.0) 65.1 (±19.1) <0.0001
  • ▪

    t2 FVC.

 101.6 (±17.6) 94.5 (±20.0) 0.126

Legend: dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous systemic sclerosis; mRSS: modified Rodnan skin score; ACA: anticentromere antibodies, Topo-I: anti-topoisomerase I antibodies; RNA-Pol III: anti-RNA polymerase III antibodies.